Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: Understanding infection and coinfection risks in a nonurban population

American Journal of Public Health

Volumn 104, Issue 9, 2014, Pages 1713-1721

  Akselrod, Hana ^a,b   Grau, Lauretta E ^a   Barbour, Russell ^a   Heimer, Robert ^a  

^a YALE UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD; DEPRESSION; DRUG OVERDOSE; EPIDEMIOLOGY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; MIXED INFECTION; RISK FACTOR; SOCIOECONOMICS; SUBSTANCE ABUSE; TIME; UNITED STATES;

ADULT; COINFECTION; CONNECTICUT; DEPRESSION; DRUG OVERDOSE; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

EID: 84906077590     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2013.301357     Document Type: Article

References (46)

1. Baumann BM, Mazzarelli A, Brunner J, Chansky ME, Thompson N, Boudreaux ED. Purchase and use patterns of heroin users at an inner-city emergency department. JEmergMed. 2012;42(1):93-99.
2. Centers for Disease Control and Prevention. Trends in injection drug use among person entering addiction treatment-New Jersey, 1992-1999. MMWRMorb Mortal WklyRep. 2001;50(19):378-381.
3. Cicero TJ, Surratt H, Inciardi JA, Munoz A. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf. 2007; 16 (8):827-840.
4. SAMHSA Office of Applied Statistics. National Survey on Drug Use &Health. US Department of Health &Human Services. 2011. Available at: http://www.oas. samhsa.gov/nsduh/reports.htm. Accessed September 27, 2011.
5. Thorpe LE, Bailey SL, Huo D, Monterosso ER, Ouellet LJ. Injection-related risk behaviors in young urban and suburban injection drug users in Chicago (1997-1999). J Acquir Immune Defic Syndr. 2001;27 (1):71-78.
6. Estrada AL. Health disparities among African-American and Hispanic drug injectors-HIV, AIDS, hepatitis B virus and hepatitis C virus: a review. AIDS. 2005;19(suppl 3):S47-S52.
7. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS. 2011;6(6):478-482.
8. Kim JH, Psevdos G, Suh J, Sharp VL. Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus-infected patients in New York City, United States. World Gastroenterol. 2008;14(43):6689-6693.
9. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection-A global challenge. N Engl Med. 2012;366(19):1749-1752.
10. Fox T, Leukhardt B. Small town, big-time heroin use. Hartford Courant. October 20, 2002:3.
11. Grund JP, Heckathorn DD, Broadhead RS, Anthony DL. In eastern Connecticut, IDUs purchase syringes from pharmacies but don't carry syringes. J Acquir Immune DeficSyndr. 1995;10(1):104-105.
12. Green TC, Grau LE, Colon N, Carver HW, Kinzly ML, Heimer R. Epidemiological trends in fatal opioid intoxications in Connecticut: 1997-2007. Drug Alcohol Depend. 2011;115(3):221-228.
13. HeimerR, BluthenthalRN, SingerM, Khoshnood K. Structural impediments to operational syringe exchange programs. AIDS Public Policy J. 1996;11(4):169-184.
14. Paone D, Des Jarlais DC, Caloir S, Jose B, Shi Q, Friedman S. Continued risky injections subsequent to syringe exchange use among injection drug users in New York City. AIDS Educ Prev. 1997;9(6):505-510.
15. Singer M, Stopka T, Siano C, et al. The social geography of AIDS and hepatitis risk: qualitative approaches for assessing local differences in sterile-syringe access among injection drug users. Am JPublic Health. 2000;90(7):1049-1056.
16. Buchanan D, Shaw S, Teng W, Hiser P, Singer M. Neighborhood differences in patterns of syringe access, use, and discard among injection drug users: implications for HIV outreach and prevention education. JUrban Health. 2003;80(3):438-454.
17. Birkhead GS, Klein SJ, Candelas AR, et al. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach. Int JDrugPolicy. 2007;18(5): 417-425.
18. Dumont DM, Brockman B, Dickman S, Alexander N, Rich JD. Public health and the epidemic of incarceration. Annu Rev Public Health. 2012;33:325-339.
19. Rich JD, Wakeman SE, Dickman SL. Medicine and the epidemic of incarceration in the United States. N Engl JMed. 2011;364(22):2081-2083.
20. Santibanez SS, Garfein RS, Swartzendruber A, Purcell DW, Paxton LA, Greenberg AE. Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States. JUrban Health. 2006;83(1):86-100.
21. Heckathorn D. Respondent driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Soc Probl. 2002;49(1): 11-34.
22. Salganik MJ, Heckathorn DD. Sampling and estimation in hidden populations using respondent-driven sampling. Sociol Methodol. 2004;34(1):193-240.
23. MetzgerDS, Koblin B, TurnerCF, etal. Randomized controlled trial of audio computer-Assisted self-interviewing: utility and acceptability in longitudinal studies. HIV-NET Vaccine Preparedness Study Protocol Team. Am J Epidemiol. 2000;152(2):99-106.
24. TurnerCF, KuL, RogersSM, LindbergLD, Pleck JH, Sonenstein FL. Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science. 1998;280(5365):867-873.
25. Grau LE, Dasgupta N, Harvey AP, et al. Illicit use of opioids: is oxycontin a "gateway drug"? Am J Addict. 2007;16(3):166-173.
26. Grau LE, White E, Niccolai LM, et al. HIV disclosure, condom use, and awareness of HIV infection among HIV-positive, heterosexual drug injectors in St. Petersburg, Russian Federation. AIDS Behav. 2011;15 (1):45-57.
27. Heimer R, Grau LE, Curtin E, Khoshnood K, Singer M. Assessment of HIV testing of urban injection drug users: implications for expansion of HIV testing and prevention efforts. Am JPublic Health. 2007;97(1): 110-116.
28. Heimer R, Clair S, Grau LE, Bluthenthal RN, Marshall PA, Singer M. Hepatitis-Associated knowledge is low and risks are high among HIV-Aware injection drug users in three US cities. Addiction. 2002;97(10):1277-1287.
29. HeimerR, Khoshnood K, BiggD, GuydishJ, Junge B. Syringe use and re-use: effects of syringe exchange programs in four cities. J Acquir Immune Defic Syndr. 1998;18(Suppl. 1):S37-S44.
30. Niccolai LM, Toussova OV, Verevochkin SV, Barbour R, Heimer R, Kozlov AP. High HIV prevalence, suboptimal HIV testing, and low knowledge of HIV-positive serostatus among injection drug users in St. Petersburg, Russia. AIDS Behav. 2010;14(4):932-941.
31. Niccolai LM, Verevochkin SV, Toussova OV, et al. Estimates of HIV incidence among drug users in St. Petersburg, Russia: continued growth of a rapidly expanding epidemic. Eur JPublic Health. 2011;21(5): 613-619.
32. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. JSubst Abuse Treat. 1992;9(3):199-213.
33. McLellan AT, Luborsky L, O'Brien CP, Woody GE. An improved diagnostic instrument for substance abuse patients, the Addiction Severity Index. JNerv Ment Dis. 1980;168(1):26-33.
34. Stoffelmayr BE, Mavis BE, Kasim RM. The longitudinal stability of the Addiction Severity Index. J Subst Abuse Treat. 1994;11(4):373-378.
35. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385-401.
36. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring anxiety: psychometric properties. JConsult Clin Psychol. 1988;56(6):893-897.
37. Beck AT, Steer RA. Beck Anxiety Inventory Manual. San Antonio, TX: The Psychological Corp., Harcourt Brace &Co.; 1993.
38. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31(7):1208-1217.
39. Bush K, Kivlahan DR, McDonnell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158(16):1789-1795.
40. Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, eds. Advances in Pain Research and Therapy: Issues in Pain Management. Vol 12. New York, NY: Raven Press; 1989:391-403.
41. Keller S, Bann CM, Didd SL, Schein J, MendozaTR, Cleeland CS. Validity of the Brief Pain Inventory for use in documenting the outcomes ofpatients with noncancer pain. Clin JPain. 2004;20(5):309-318.
42. Metzger DS, Woody GE, O'Brien CP. Drug treatment as HIV prevention: a research update. JAcquir Immune Defic Syndr. 2010;55(Suppl 1):S32-S36.
43. Sorensen JL, Copeland AL. Drug abuse treatment as an HIV prevention strategy: a review. DrugAlcohol Depend. 2000;59(1):17-31.
44. Pollack HA, Heimer R. The impact and cost-effectiveness of methadone maintenance treatment in preventing HIV and hepatitis C. In: Weissing L, Jager JC, eds. Impact and Costs ofHepatitis C in InjectingDrugUsers in the European Union. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction; 2003:345-367.
45. Turner KM, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978-1988.
46. Office of Juvenile Justice and Delinquency Prevention. The Socioeconomic Mapping and Resource Topography (SMART) system. US Department of Justice. Available at: http://smart.gismapping.info. Accessed July 10, 2012.